Personalis/$PSNL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Personalis

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Ticker

$PSNL
Sector
Primary listing

Employees

229

Personalis Metrics

BasicAdvanced
$519M
-
-$1.18
1.87
-

What the Analysts think about Personalis

Analyst ratings (Buy, Hold, Sell) for Personalis stock.

Bulls say / Bears say

Clinical test volume jumped 59% sequentially to 3,478 tests in Q2 2025—up from 2,184 in Q1—showing faster uptake of the NeXT Personal® platform by doctors (Business Wire)
Personalis expanded its exclusive commercialization agreement with Tempus AI to now cover colorectal cancer, significantly increasing its market potential and strengthening its commercial partnership in a key new area (Business Wire)
Pharma tests and services revenue rose 39% year-over-year to $13.6 million in Q1 2025, boosting total revenues to $20.6 million and reflecting strong demand for Personalis’ genomic sequencing and analytics offerings (Business Wire)
Q2 2025 revenue dropped 24% year-over-year to $17.2 million, coming in below the Q1 outlook of $19.5–20.5 million, highlighting the impact of timing fluctuations in biopharma projects (Business Wire)
Personalis lowered its full-year 2025 revenue forecast by 12.5% at the midpoint, reducing the range from $80–90 million down to $70–80 million, citing delays in key biopharma contract revenue (Investing.com)
Gross margin shrank by eight percentage points to 27.6% in Q2 2025 driven by lower volume and higher costs for clinical tests not reimbursed, putting profitability under pressure (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.

Personalis Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Personalis Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PSNL

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy Personalis stock | $PSNL Share Price | Lightyear